ライフサイエンスコーパス: intraocular tumor

1 This led to the discovery of a multicystic intraocular tumor.

2 e growth of a highly vascularized angiogenic intraocular tumor.

3 agent on the growth of a highly vascularized intraocular tumor.

4 cedure, PLSU can achieve control of selected intraocular tumors.

5 herapy with sonoporation in the treatment of intraocular tumors.

6 the failure to induce Th17 cells within the intraocular tumors.

7 ated killing of tumor cells and rejection of intraocular tumors.

8 a significant decrease (P = 0.01) in viable intraocular tumors.

9 observed nor necessary for rejection of the intraocular tumors.

10 of CD8+ T cells in the pristine rejection of intraocular tumors.

11 e and prevents the rejection of NK-sensitive intraocular tumors.

12 IFN-gamma knockout mice that fail to reject intraocular tumors, 5) CD4(+) T cells and corneal endoth

13 nosis was obtained in 97.6% (n = 121) of the intraocular tumors, and chromosome 3 status could be det

14 delivery of paclitaxel effectively inhibits intraocular tumor burden in the LH beta-Tag model of ret

15 nited States are diagnosed as having a large intraocular tumor burden that requires intensive ocular-

16 An enucleation was performed, and an intraocular tumor composed almost entirely of rhabdomyob

17 er eye with intraocular disease) in whom the intraocular tumor did not show (18)F-FDG uptake.

18 her supported by investigations showing that intraocular tumors grew progressively in IFN-gamma KO (k

19 A dose-dependent inhibition of intraocular tumor growth by carboplatin was observed in

20 oplatin in serial doses effectively inhibits intraocular tumor growth in a dose-dependent manner in t

21 chemotherapy agents in a novel setting (ie, intraocular tumor) has been successful in treating all b

22 Uveal melanoma is the most common intraocular tumor in adults and is derived from tissues

23 carboplatin safely and effectively controls intraocular tumors in a dose-dependent manner in this mu

24 d studied the methylome in the most frequent intraocular tumors in adults and children (uveal melanom

25 biopsies were performed in 123 patients with intraocular tumors in the posterior segment from January

26 r data indicate that the function of FasL on intraocular tumors is determined by the microenvironment

27 18.7%) were the most common, correlating to intraocular tumor location (P<0.001).

28 However, tumor LBD, tumor thickness, and intraocular tumor location also proved to be significant

29 Retinoblastoma is the most common malignant intraocular tumor of childhood.

30 Of the 41 treatment-naive eyes, a new intraocular tumor (one focus) subsequently developed in

31 For all intraocular tumors, optical coherence tomography provide

32 d eyes injected with CD34(+) cells showed no intraocular tumor or abnormal tissue growth after 8 mont

33 redictive of extraocular tumor extension was intraocular tumor recurrence after TTT treated with addi

34 ells circumvent immune privilege and mediate intraocular tumor rejection by a TNF-alpha-dependent man

35 cells from tumor-rejector mice could mediate intraocular tumor rejection following adoptive transfer

36 Intraocular tumor rejection required CD4(+) T cells, but

37 se to Ad5E1 tumor Ags or use FasL to mediate intraocular tumor rejection.

38 Although intraocular tumors reside in an immune privileged site,

39 Although intraocular tumors reside in an immune-privileged enviro

40 Although intraocular tumors reside in an immune-privileged site w

41 Conclusion Intraocular tumor size shows a strong association with p

42 Uveal melanoma (UM) is a rare intraocular tumor that, similar to cutaneous melanoma, o

43 Y79 retinoblastoma cells formed intraocular tumors that were initially confined to the v

44 step toward developing an immunotherapy for intraocular tumors, the present study was conducted to e

45 was used as a screening tool to evaluate the intraocular tumor, to evaluate for multi-organ metastati

46 The intraocular tumor was detectable in 28% of cases.

47 A dose-dependent inhibition of intraocular tumor was observed after repetitive iontopho

48 Intraocular tumor weights were determined on days 10, 14

49 The sizes of the intraocular tumors were determined.

50 es of transgenic mice that develop pigmented intraocular tumors were produced with the SV40 T and t a

51 lines of transgenic mice developed bilateral intraocular tumors with complete penetrance and without